Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 10/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143191 | 0.89 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL146902 | 0.88 | GPR119 (0.45) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL143233 | 0.80 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL143156 | 0.80 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL146316 | 0.78 | GPR119 (0.43) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL143231 | 0.77 | GPR119 (0.47) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL9206368 | 0.77 | PDE4B (0.46) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL146390 | 0.76 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL143942 | 0.75 | GPR119 (0.45) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7800478 | 0.73 | GPR119 (0.47) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-0539806-B1 | Thiadiazinones and medicines containing them, having in particular a positive inotropic and vasodilating activity | MERCK PATENT GMBH (DE) | 1995-01-04 | — | — | EP | disclosed |
| US-5276027-A | Thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0539806-A1 | Thiadiazinones and medicines containing them, having in particular a positive inotropic and vasodilating activity | MERCK PATENT GmbH (DE) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | PDE4A 1401/4885PDE4B 1040/4885PDE4C 1797/4885 |
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | PDE4A 1401/4885PDE4B 1040/4885PDE4C 1797/4885 |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.